In this context, If the phrase "patched" becomes a regulatory designation (similar to "PEGylated" or "Fc-fused"), Neoepobin will be remembered as the first molecule to cross that threshold.
As of mid-2026, the regulatory path for is aggressive. The FDA has granted it Rare Pediatric Disease Designation for treatment of Krabbe disease (a leukodystrophy in infants) and Fast Track status for Progressive Supranuclear Palsy. neoepobin patched
: Patches typically require less frequent administration compared to multiple daily doses of other medications. Common Side Effects In this context, If the phrase "patched" becomes